MétaCan
← all works

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

2003· review· en· 2,163 citations· W2136284733 on OpenAlex· 10.1136/bmj.326.7400.1167

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.

Machine scores (provisional)

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Opus teacher head0.919
GPT teacher head0.749
Teacher spread
0.170 · how far apart the two teachers sit on this one work
Validation status
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

OBJECTIVE: To investigate whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support. METHODS: Medline (January 1966 to December 2002) and Embase (January 1980 to December 2002) searches were supplemented with material identified in the references and in the authors' personal files. Data were independently abstracted by three of the authors and disagreements were resolved by consensus. RESULTS: 30 studies were included. Research funded by drug companies was less likely to be published than research funded by other sources. Studies sponsored by pharmaceutical companies were more likely to have outcomes favouring the sponsor than were studies with other sponsors (odds ratio 4.05; 95% confidence interval 2.98 to 5.51; 18 comparisons). None of the 13 studies that analysed methods reported that studies funded by industry was of poorer quality. CONCLUSION: Systematic bias favours products which are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product being investigated and publication bias.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue
BMJ
Topic
Pharmaceutical industry and healthcare
Field
Pharmacology, Toxicology and Pharmaceutics
Canadian institutions
York University
Funders
Keywords
Pharmaceutical industryMEDLINEOdds ratioPublication biasMeta-analysisDrug industryQuality (philosophy)Conflict of interestMedicineSystematic reviewFamily medicineConfidence intervalProduct (mathematics)Alternative medicineBusinessPolitical sciencePharmacologyInternal medicineEngineering
Has abstract in OpenAlex
yes